pharmaphorum

DECEMBER 29, 2020

NHS England’s chief executive Sir Simon Stevens has said that all vulnerable people over the age of 50 will be offered a COVID-19 vaccine by “late spring” in a message to healthcare workers. The prediction comes after the NHS announced on Christmas Eve that more than half a million people had received the Pfizer/BioNTech shot approved in early December, but will depend on additional vaccine supplies coming “on stream”, according to Stevens.

Vaccines 105

Vaccines Hospitals 105

Pharma Marketing Network

DECEMBER 29, 2020

2020 was a year defined by unexpected challenges – and related opportunity – for pharmaceutical marketers. The COVID-19 pandemic pushed the industry to experiment with new media, emerging technologies and innovative platforms to keep physicians, providers and patients informed, engaged and empowered. As telehealth appointments replaced office visits, webinars replaced in-person conferences and digital communication replaced reps in the field, what have we learned about how to create connec

Communication 98

Communication 98

Druggist

DECEMBER 28, 2020

Fexofenadine recently received a green light and soon will be available over the counter without a prescription. Until now, fexofenadine was a prescription-only medication. The Government recently announced the reclassification of fexofenadine 120mg, which will be available as General sale Medication (GSL), sold as branded products – Allevia 120mg tablets.

98

98

Med Ed 101

DECEMBER 30, 2020

It is well known that we create study materials for several board exams. I’m often one of the first to know when changes happen because people ask me how it should impact their preparations! The 2021 BCMTMS Exam changes are some of the most expansive that I have seen to any board exam. You must […]. The post 2021 BCMTMS Exam Changes and Why It Will Be Harder appeared first on Med Ed 101.

40

40

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

DECEMBER 30, 2020

The UK has approved AstraZeneca and Oxford University’s COVID-19 vaccine AZD1222 in another significant step forward in the fight against the pandemic, with first doses due to be administered on Monday. The UK government has already ordered 100 million doses of the adenovirus-based shot, enough to vaccinate 50 million people, adding to the 40 million dose order of the Pfizer/BioNTech shot – now known as Comirnaty – that was approved earlier this month.

Vaccines 98

Vaccines Hospitals 98

Druggist

DECEMBER 31, 2020

Vibegron (brand name: Gemtesa) is the latest drug used to treat overactive bladder that has been approved by the FDA in the USA. Gemtesa will be available in the US as prescription-only medication from April 2021. In this post, I will summarise: . Licensed use and legal status of vibegron (US). It’s a mechanism of action . The effectiveness of vibegron: summary of clinical trial . vibegron vs mirabegron: what is the difference?

FDA 59

FDA 59

Druggist

DECEMBER 26, 2020

Today I will review anti-sickness tables which are available over the counter from a pharmacy. Most commonly used anti-sickness tablets over the counter in the UK are drugs used for motion sickness. There are, however, other options for the management of sickness associated with migraines or nausea caused by other medications including radiotherapy.

52

52

pharmaphorum

DECEMBER 31, 2020

The post-Brexit trade deal agreed on Christmas Eve has been overwhelmingly backed by the UK parliament, providing some degree of stability – but also plenty of disruption – for the coming months and years. The UK is leaving the EU’s single market and customs union, but the deal means tariffs on goods won’t be imposed when the transition period ends at 23:00 GMT tonight.

Documentation 52

Documentation 52